外科理论与实践2026，Vol.31Issue(3)：227-233,7.DOI:10.16139/j.1007-9610.2026.03.08
CDK4/6抑制剂在早期乳腺癌辅助治疗应用的热点问题
Topical topics of CDK4/6 inhibitors in adjuvant treatment of early breast cancer
摘要
Abstract
Hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2-)breast cancer is the predominant molecular subtype.However,even after completion of standard adjuvant endocrine therapy,patients of this subtype continue to face a persistent risk of late recurrence.Cyclin-dependent kinase 4/6(CDK4/6)inhibitors precisely target dysregulated cell-cycle progression.They have been proved to significantly reduce the risk of recurrence in high-risk early-stage patients in the adjuvant setting,thereby reshaping the treatment landscape of HR+/HER2-early breast cancer.This review systematically summarized the key evidence supporting adjuvant CDK4/6 inhibitor therapy,critically analyzed current controversies in clinical practice,outlined major recommendations from international and national guidelines,discussed strategies for individualized treatment optimization,and provided perspectives on future research directions.These insights may help inform the standardized and precise use of CDK4/6 inhibitors for patients of early breast cancer.关键词
CDK4/6抑制剂/HR+/HER2-乳腺癌/早期乳腺癌/辅助治疗/复发风险Key words
CDK4/6 inhibitors/HR+/HER2-breast cancer/Early breast cancer/Adjuvant therapy/Recurrence risk分类
医药卫生引用本文复制引用
徐佳妍,朱思吉..CDK4/6抑制剂在早期乳腺癌辅助治疗应用的热点问题[J].外科理论与实践,2026,31(3):227-233,7.基金项目
国家自然科学基金(82573726) （82573726）
